

# An *ATM* homologue from *Arabidopsis thaliana*: complete genomic organisation and expression analysis

Valérie Garcia, Marcel Salanoubat<sup>1</sup>, Nathalie Choisne<sup>1</sup> and Alain Tissier\*

CEA/Cadarache, DSV, DEVM, Laboratoire de Radiobiologie Végétale, 13108 St Paul-lez-Durance Cedex, France and <sup>1</sup>Centre National de Séquençage, 2 rue Gaston Crémieux, CP 5706, 91057 Evry cedex, France

Received January 27, 2000; Revised and Accepted March 3, 2000

DDBJ/EMBL/GenBank accession no. AJ250248

## ABSTRACT

*ATM* is a gene mutated in the human disease ataxia telangiectasia with reported homologues in yeast, *Drosophila*, *Xenopus* and mouse. Whenever mutants are available they all indicate a role of this gene family in the cellular response to DNA damage. Here, we present the identification and molecular characterisation of the first plant homologue of *ATM*. The genomic locus of *AtATM* (*Arabidopsis thaliana* homologue of *ATM*) spans over 30 kb and is transcribed into a 12 kb mRNA resulting from the splicing of 79 exons. It is a single copy gene and maps to the long arm of chromosome 3. Transcription of *AtATM* is ubiquitous and not induced by ionising radiation. The putative protein encoded by *AtATM* is 3856 amino acids long and contains a phosphatidylinositol-3 kinase-like (Pi3k-I) domain and a rad3 domain, features shared by other members of the *ATM* family. The *AtAtm* protein is highly similar to *Atm*, with 67 and 45% similarity in the Pi3k-I and rad3 domains respectively. Interestingly, the N-terminal portion of the protein harbours a PWWP domain, which is also present in other proteins involved in DNA metabolism such as human mismatch repair enzyme Msh6 and the mammalian *de novo* methyl transferases, Dnmt3a/b.

## INTRODUCTION

In all living cells, DNA damage induces a variety of responses which contribute to maintaining the integrity of the genome. In eukaryotic cells, these include DNA repair, cell cycle arrest and, for multicellular organisms, apoptosis (1). DNA repair and cell cycle arrest are distinct but complementary genome-preserving responses whereas DNA damage-induced apoptosis prevents the transmission of misrepaired lesions which may have oncogenic potential. Apoptosis may therefore be seen as a genome-preserving response at the level of the organism.

Recent advances in the understanding of the signalling pathways leading to these responses have stemmed from studies of the human disease ataxia telangiectasia (AT). AT patients present a number of symptoms, some of which—e.g.

impaired fertility, proneness to develop certain cancers, hypersensitivity to ionising radiation (IR)—suggest a relation to DNA damage (2,3). AT cells are hypersensitive to IR and defective in G<sub>1</sub>/S and S-phase DNA damage checkpoints, the latter resulting in radio-resistant DNA synthesis (4,5). These defects probably contribute to the radiation sensitive phenotype of AT cells, but there is also evidence for a defect in DNA repair (6,7)

The cloning of the gene responsible for the AT disease, ataxia telangiectasia mutated (*ATM*), revealed that *Atm* is a large protein with a Pi-3 kinase-like (Pi3k-I) domain at its C-terminus (8,9), a feature shared by the cell cycle regulators Tor1 and Tor2 from yeast and their mammalian counterpart Frap/Raft (10–13). Whereas the Tor family of proteins are not involved in the control of DNA damage responses, other proteins with a Pi3k-I domain and more closely related to *Atm* were found to play a role in DNA damage responses. These include Tel1 and Mec1 from budding yeast (14,15), rad3 from fission yeast (16), mei-41 from *Drosophila* (17), and the mammalian proteins DNA-PKcs (18) and Atr (16,19). They are all very large proteins of over 2500 amino acids with little homology outside the Pi3k-I domain except in a poorly defined region of approximately 1000 amino acids which includes the rad3 domain.

Despite the presence of a Pi3k-I domain, *Atm* and other members of the family appear to be protein rather than lipid kinases. For example, p53 was shown to be phosphorylated *in vitro* on Ser15 by *Atm* (20,21). Because Ser15 phosphorylation is involved in p53 stabilisation, this may explain the delayed accumulation of p53 in AT cells in response to IR, as well as the G<sub>1</sub>/S checkpoint defect (22). Other potential phosphorylation targets include Replication Protein A (RPA) and the oncogene protein c-abl (23–25). In budding yeast, Mec1 is necessary for the phosphorylation of Rad53, a DNA damage checkpoint kinase (26) and overexpression of Tel1 partially rescues *mec1* mutants, including by restoring the phosphorylation of Rad53 (14,27). This indicates that both yeast *Atm* homologues have partially overlapping roles. In addition, phosphorylation of Rpa and Rad9 after DNA damage requires the presence of active Mec1 (28,29). Also, in fission yeast, activation of the checkpoint kinases cds1 (a *RAD53* homologue) and chk1 depends on rad3 (30). The identification of chk1 and cds1 structural and functional homologues in mammals further underlines the conservation of the DNA damage checkpoint pathways among eukaryotic organisms (31,32).

\*To whom correspondence should be addressed. Tel: +33 4 42 25 77 28; Fax: +33 4 42 25 46 56; Email: atissier@cea.fr

This conservation led us to postulate the existence of similar mechanisms in plants. We describe here the cloning an *Arabidopsis thaliana* homologue of *ATM*.

## MATERIALS AND METHODS

### New sequence

EMBL accession number AJ250248. *Arabidopsis thaliana* homologue of *ATM*.

### Plant material, cell culture and irradiation experiments

*Arabidopsis thaliana* var. Colombia plants were cultivated in a growth chamber on a 16/8 h light/dark cycle. *Arabidopsis thaliana* var. Colombia cell suspension (33) was grown in liquid medium described by Chandler (34) at 28°C in an orbital shaker (120 r.p.m.) and under continuous light (60  $\mu\text{mol photons/m}^2/\text{s}$ ). Cells were collected in the exponential phase of growth and irradiated with various doses of  $\gamma$  rays using a  $^{60}\text{Co}$  source at a dose rate of 30 Gy/min. For time course analysis, cells were put back in the shaker for the required time period, filtered, dried and flash-frozen in liquid nitrogen. Samples were stored at -80°C or immediately ground for RNA extraction.

### Physical mapping and sequencing of the BAC clone

The insert of EST number T43304 was hybridised to the TAMU BAC library filter. Six positive clones were identified (T1F6, T3G4, T23E4, T24C20, T25D10, T28I7). Corresponding IGF BAC clones were found using the BAC fingerprint database (<http://genome.wustl.edu/gsc/arab/arabidopsis.html>). The physical map position was then determined with the IGF mapping table ([http://www.mpimp-golm.mpg.de/101/mpi\\_mp\\_map/bac.html](http://www.mpimp-golm.mpg.de/101/mpi_mp_map/bac.html)).

Sequencing of BAC clone T24C20 was done at the Genoscope, as part of the European contribution to the *Arabidopsis* Genome Initiative. 20  $\mu\text{g}$  of DNA were sheared using a HydroShear apparatus (Genemachines) and the resulting fragments were repaired using T4 DNA polymerase. The fragments were ligated to *Bst*XI adaptors and separated on a preparative 0.4% LMP agarose gel (FMC). The DNA fractions of 3 kb were eluted on Qiaquick (Qiagen) and then ligated to a *Bst*XI-digested pcDNA2.1 plasmid (Invitrogen) in a 10 $\times$  insert/1 $\times$  vector ratio before transformation of electrocompetent *Escherichia coli* strain DH10B (Gibco BRL). We isolated 800 subclones (seven genome equivalents) and sequenced the end clones on a LICOR 4200 sequencer and assembled the sequences using Phred and Phrap software, which resulted in the construction of a scaffold composed of several contigs. The gaps and poor quality regions were sequenced by primer walking with dye terminators on an automated ABI 377 sequencer (PE-Applied Biosystems). The resulting sequence was then analysed by comparing restriction digest using three different restriction enzymes to the restriction pattern deduced from the sequence.

### RNA isolation

Total RNA was prepared from 2 g of frozen plant tissues (20 day-old plants) and from cultured cells according to Kloppstech *et al.* (35). Poly(A)<sup>+</sup> mRNA was prepared as described by Montané *et al.* (36).

### Reverse transcription (RT)-PCR and determination of transcript structure


RT-PCR was performed on poly(A)<sup>+</sup> mRNA (1  $\mu\text{g}$ ) with Expand<sup>TM</sup> Reverse Transcriptase and specific primers according to the manufacturer's instructions (Boehringer Mannheim, Germany). Based on genomic sequence and structure prediction (GENSCAN software) 86 PCR primers were designed. The sequence of these primers is available from the authors on request. The first-strand cDNA synthesis reaction products were amplified by PCR using various primer combinations. The initial denaturation was done at 94°C for 2 min, then amplification was performed for at least 30 cycles with a denaturation time of 30 s at 94°C, followed by annealing at different temperatures (depending on primers) and extension for different times at 72°C.

For rapid amplification of cDNA ends (5' RACE) experiments, first-strand cDNA synthesis was performed as described above, with primer *AtATM63* (5'-TCTGTTTCGCTGAACGA-CAACGCGAAG-3'), and followed by a phenol/chloroform extraction. A string of deoxyguanosine was added at the 3' end of the cDNA with DNA Terminal Transferase (New England Biolabs) according to the manufacturer's instructions and a first PCR was performed with 250 pmol of primer *AtATM61* (5'-TGCTGAGTGTATCTGCCGTCATAGC-3') and primer *AtATM83* [5'-(GA)<sub>12</sub>GCTCACTAGT(C)<sub>14</sub>-3'] using *Taq* DNA polymerase (Sigma). The initial denaturation was done at 94°C for 2 min, then amplification was performed for 30 cycles with a denaturation time of 30 s at 94°C, followed by annealing at 55°C for the first 5 cycles and at 63°C for the remaining 25 cycles, and extension for 2 min at 72°C. Following the first PCR, 1  $\mu\text{l}$  of a 10-fold dilution of the reaction mixture was added to the second PCR reaction mixture containing primers *AtATM83* and *AtATM84* (5'-CGAAGAAGCGAACCAC-GAAACAAGATGG-3'). The initial denaturation was done at 94°C for 2 min, then amplification was performed for 30 cycles with denaturation time of 30 s at 94°C, followed by annealing at 62°C for 30 s and extension for 90 s at 72°C.

PCR products were sequenced with the BigDye terminator kit (PE-Applied Biosystems) and analysed on an ABI Prism 310 sequencing machine (PE-Applied Biosystems).

### Semi-quantitative RT-PCR

For semi-quantitative RT-PCR, 1  $\mu\text{g}$  of total RNA from tissues was reverse transcribed as described above using 5  $\mu\text{M}$  of primer 5'-VN-(T)<sub>11</sub>-3', and cDNA were diluted 2-fold. Aliquots of each dilution (1  $\mu\text{l}$ ) were used for PCR with either 5  $\mu\text{M}$  *AtATM* (*Atatm89* 5'-CTACCTTTCTATTGGTATCCTCTCT-CCTT-3' and *Atatm14* 5'-TCTGCATTGGTTTCGCTTATC-3') or *ACT8* (*act-8.3* 5'-GCACTTTCCAGCAGGTATGGATCTCTAAGGCA-3' and *act-8.4* 5'-CCGGAAAGTTTCTCACATAGTGAC-3') specific primers, in the presence of 250  $\mu\text{M}$  of each dNTP and 1 U of *Taq* polymerase (Sigma) in 10 mM Tris-HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl<sub>2</sub> and 0.001% gelatin. Cycling conditions were identical to those set out above for cDNA cloning except that the number of cycles was reduced (25 for *act-8* primers and 30 for *AtATM* primers). Reaction products were separated on 1% agarose gels, transferred to a Nylon membrane (Hybond N<sup>+</sup>, Amersham Life Sciences), and hybridized with <sup>32</sup>P-labelled fragments.



**Figure 1.** (a) Schematic of the exon–intron structure of the *AtATM* gene drawn to scale. All coding exons are represented by black boxes; the first exon, which is non-coding, by a white box. (b) Schematic of the primary structure of the AtAtm protein. PWWP, hath or PWWP domain; ATM, similarity to human Atm; rad3, rad3 domain; CC, coiled-coil domain; Pi3k, phosphatidylinositol-3 kinase-like domain; C-ter, C-terminal domain characteristic of the Atm/Tor family of proteins.

Hybridisation signals were quantified using a PhosphorImager (Molecular Dynamics)

### Northern blot analysis

For northern blot analysis, poly(A)<sup>+</sup> RNA (5 µg/lane) were separated on formaldehyde gels in 1× MOPS buffer and transferred to a Nylon membrane (Hybond N<sup>+</sup>, Amersham Life Sciences) as described by Sambrook *et al.* (37). Gels were stained with ethidium bromide to ensure that equal amounts had been loaded. Hybridisation was performed overnight at 65°C with <sup>32</sup>P-labelled fragments in a solution containing 0.5 M NaH<sub>2</sub>PO<sub>4</sub> pH 7.2, 5% SDS, 5 mM EDTA. Labelling of probes was performed with the Megaprime DNA labelling system (Amersham Life Sciences) using 50 µCi of [ $\alpha$ -<sup>32</sup>P]dCTP. Filters were washed twice at 65°C for 10 min in 1× SSC, 0.1% SDS, and 10 min in 0.2× SSC, 0.1% SDS. Filters were exposed to X-ray film (Kodak) or to an imaging plate.

## RESULTS

We first found an *Arabidopsis* EST (GenBank accession number T43304) with potential homologies to *ATM* by a word search in the dbEST database. The translated EST sequence showed similarities to a domain just upstream of the Pi3k-1 domain. The EST clone was sequenced and found to contain a 1.7 kb insert corresponding to the 3' end of a mRNA encoding a Pi3K-1 domain. Initial BLAST searches (38) with this sequence confirmed a strong similarity with Atm-like proteins and we named it *AtATM* (*A.thaliana* homologue of *ATM*). Preliminary northern hybridisation showed the presence of a 12 kb mRNA (see below). We screened an *Arabidopsis* cDNA library (39) to obtain larger clones and found one clone with a 3.4 kb chimeric insert of which 2.9 kb corresponded to the 3' end of the *AtATM* transcript. After several unsuccessful 5' RACE attempts, we decided to first characterise the genomic locus of *AtATM*.

### Isolation and sequencing of the genomic locus

The EST fragment was hybridised to the Texas A&M University (TAMU) bacterial artificial chromosome (BAC) library filters (40). Five BAC clones were found to contain the *AtATM* locus. The Institut für Genbiologische Forschung (IGF) BAC clones with matching restriction fingerprints were found using the

fingerprint database. This allowed us to position the gene on chromosome 3 between RFLP markers m409 and I18. All the positive BAC clones mapped to the same chromosomal region suggesting it is a single locus and possibly a single copy gene. This was confirmed by Southern blotting and hybridisation (data not shown). Next, we focused on BAC clone T24C20 and completely sequenced it. The annotated sequence is now available (EMBL accession number AL096856). The genomic region corresponding to the EST was identified and in order to position a possible 5' end of the gene we performed BLAST searches with 5 kb genomic fragments upstream of the EST. A region with homology to betaine aldehyde dehydrogenase was found ~35 kb upstream of the EST region and in the opposite orientation. This suggested that the *AtATM* gene is contained within these 35 kb.

### Determination of the *AtATM* mRNA structure by RT-PCR

We then used the GENSCAN software (41) to predict potential translation initiation, donor and acceptor splice sites respectively. This prediction helped us design primers to amplify cDNA fragments by RT-PCR and thus to determine the complete structure of the *AtATM* gene. The transcript is 11.8 kb long and composed of 79 exons. Several exons were not predicted by GENSCAN or by the annotation from the Munich Information Center for Protein Sequences (MIPS). The exon–intron junctions are presented in Table 1 where they are compared with the annotation of MIPS. The 5' end of the transcript was determined by 5' RACE with primers located in the second exon. This exon of 2.8 kb is unusually long relative to the other exons and contains a potential Met initiator codon. The first exon does not contain in-frame Met codons, nor an uninterrupted in-frame ORF, and is thus presumed to be non-coding. Attempts at amplifying cDNA fragments with primers located further upstream failed, confirming the 5' RACE result. The complete exon–intron structure of *AtATM* is represented in Figure 1a.

### The AtAtm protein and sequence similarities

The translated product of the *AtATM* transcript is a large protein of 3856 amino acids with a predicted molecular weight of 440 kDa (EMBL accession number AJ250258). The overall structure of the protein with the various domains is presented in Figure 1b. The 350 C-terminal residues constitute the Pi3k-1 domain with a short tail of 25 amino acids at the very end

**Table 1.** Exon–intron organisation of the *AtATM* gene

exon number	position on T24C20	prediction by MIPS	exon number	position on T24C20	prediction by MIPS	exon number	position on T24C20	prediction by MIPS
1	31047-31156	no	28	45147-45193	no	54	54993-55115	idem
2	31339-33848	31296-33848	29	45273-45336	no	55	55358-55522	55406-55522
3	35576-35684	idem	30	45497-45571	idem	56	55600-55698	idem
4	35771-35914	idem	31	46046-46165	idem	57	56040-56191	idem
5	36259-36420	idem	32	46372-46557	idem	58	56312-56516	idem
6	36531-36726	idem	33	46768-46889	idem	59	56746-56793	no
7	36817-36973	idem	34	46968-47037	idem	60	56921-57004	idem
8	37093-37229	idem	35	47132-47259	idem	61	57121-57204	idem
9	37326-37413	idem	36	47416-47557	idem	62	57944-58024	idem
10	37768-37871	idem	37	47663-47803	idem	63	58141-58230	idem
11	38193-38291	idem	38	47900-48135	idem	64	58307-58369	idem
12	38940-38996	idem	39	48656-48842	idem	65	58648-58788	idem
13	39218-39299	39256-39299	40	48919-49140	idem	66	58873-58929	idem
14	39839-39913	idem	41	49641-49712	idem	67	59017-59076	idem
15	40434-40475	no	42	50041-50110	idem	68	59536-59630	idem
16	40551-40621	40514-40621	43	50608-50725	idem	69	59741-59849	idem
17	40854-40902	idem	44	50822-50945	idem	70	60042-60131	idem
18	41034-41105	40973-41105	45	51350-51484	idem	71	60234-60313	idem
19	41529-41666	idem	46	51726-51818	idem	72	60412-60490	idem
20	41765-41851	idem	47	52294-52341	no	73	60588-60635	no
21	41932-42116	idem	48	52429-52533	idem	74	60714-60813	no
22	42485-43067	idem	49	52794-52880	idem	75	60951-61082	idem
23	43150-43221	idem	50	53197-53514	idem	76	61204-61338	idem
24	43353-43727	no	51	53801-53913	idem	77	61426-61491	idem
25	43602-43727	idem	52	54265-54331	idem	78	61745-61888	61733-61862
26	44199-44326	44199-44251	53	54420-54494	idem	79	61997-62070	61997-62025
27	44887-45043	idem						

Exons–intron boundaries were determined by RT–PCR and compared with MIPS prediction on T24C20. The numbers indicate the position on BAC T24C20 sequence (EMBL accession number AL096856). Nine exons were absent on the MIPS prediction, and eight have different boundaries. Two exons (numbers 59 and 74) present non-canonical splice site.

characteristic of the *Atm*/*Tor* family of cell cycle regulators (42). Figure 2a shows an alignment of *AtAtm* with seven selected members of the family, *Atm*, *X-Atm*, *Atr*, *rad3*, *Mec1*, *Tell* and *mei-41*. Critical residues (Asp3681, Asn3686 and Asp3700) for the catalytic activity of these kinases are conserved in *AtAtm*. Over this region, *AtAtm* shares 58% identity and 67% similarity with *Atm*.

Outside the *Pi3k-I* domain, there is a large region of overall weaker sequence similarity between the various proteins of the selected group, with the exception of *X-Atm* for which the complete sequence is not yet available. The length of this similarity is variable depending on which proteins are compared. A comparison was performed with each possible pair of the selected proteins. This led us to subdivide this region into six domains common to respectively all, six, five, four, three or two members of the group (Fig. 2). Over this region, the *AtAtm* protein is more similar to *Atm* than to any other member of the group.

Several regions outside the *Pi3k-I* domain have been identified as potentially important for *Atm* function. The over-expression of a fragment containing a leucine zipper motif between residues 1217 and 1238 confers a dominant negative phenotype in human tumour cells (43). A two-hybrid search with the same fragment identified  $\beta$ -adaplin as a potential partner (44). The fragment sufficient for interaction however did not

contain the leucine zipper. A proline-rich motif between residues 1374 and 1382 was also found to be critical in the binding of *Atm* to *c-Abl* (24). Finally, an N-terminal fragment of 246 residues was found to selectively bind *p53* (45). None of these motifs seem to be conserved in *AtAtm*. A search for structural motifs, however, identified residues 3249–3288 as potentially forming a coiled-coil domain which does not appear to be present in the human *Atm* protein.

Blast searches with smaller portions of the *AtAtm* protein helped us detect the presence of a recently described domain of unknown function. This domain was first identified in a gene family with homology to the hepatoma-derived growth factor (*HDGF*) and thus called the *hath* (homologous to the amino terminus of *HGDF*) domain (46), and was also designated *PWWP* (for proline–tryptophan–tryptophan–proline) domain by others (47). In *AtAtm*, the *hath* domain is located between amino acids 100 and 155. A multiple alignment over this domain is shown in Figure 2d.

### Expression analysis

Expression was studied at the level of transcription by northern hybridisation. A transcript of ~12 kb was detected from poly(A)<sup>+</sup> mRNA of *Arabidopsis* cell suspension cultures (Fig. 3). The size of the transcript is compatible with the predicted size based on our RT–PCR analysis (see above).

**a)**

```


Atr  QLOKPKSLHIGSDGKFFIMZCKK...DDLLRQDCIMGFNLSLNLKLRGASRRRPFHRTVAVIFNDEGTFEWWNITAGLRPELTKLKEKGVVYMG.....RETRQC 2409
Rad3  SLOKPKLIVYVRCIDGNLAFPLCKK...DDLLRQDAIMGFNMLCILKLRGQANRRNLCBRTVVVPLNEEGTFEWWNITAFPSFELLSHOKNIPISY.....QELK.V 2164
Mei41  SAAKPKLITIRCSDDGKNDVLLCKK...DDLLRQDAIMGFNGLMKRYLHQGAPAFQRRLLHRTVAVIFNDEGTFEWWNITAFPSFELLSHOKNIPISY.....RQIQSL 2134
Mec1  SIKKPKRLNIIIGSDGKLIYIMZCKK...REDVRODNOYLOPATTMDFLSEKIASKRSISGNTIVSVLSRREDGGLLEWVENVITLRSILSTKPSLKKIKYSL.....RSHDR 2161
AtAtm  GINAPKIVYECFGSDGKQYKQAKSGNDDLRQDAVMEQFGLVNTFLHNNRDMKRRLLAVRTYKVIPTTEAGVLEWVDGTHPLGDYILIGSSRSEGAHCRYGICNWKYPKCRHEM 3621
X-ATM  GINAPKIVYECFGSDGKERRRLQK...GDDLRQDAVMEQFQGMONTLFRNSETPKRRLVTRFYKVPESHRSGLVLEWVDGTHPLGYSYLV...NDKPGAKRYRCEQYGSLOCQRKM 1322
Atm  GVINPKIVYECFGSDGKERRRLQK...GDDLRQDAVMEQFQGMONTLFRNSETPKRRLVTRFYKVPESHRSGLVLEWVDGTHPLGYSYLV...NNEGAKRRVRENDFSAFOQRKM 2805
Tel1  GINAPKIVYFNINSDGTTQALMKSSNDDLRQDAVMEQFQGMONTLFRNSETPKRRLVTRFYKVPESHRSGLVLEWVDGTHPLGYSYLV...KITFDARAKM 2547

Atr  MLPKSAALSFKKRVREFILRRHPIFHE...FLRTEFHPPTSMSSRSAYGRSDAVSMVGYITGLGDRHGENILLDSITCEVHDDFNCFNGETFEVPEVPPFRLLTRAMVGM 2523
Rad3  DLDFALRSFNPQDIFEKILKSEKPVYVE...EVESFHEBPNMWTSRONYRRLAVLSSVGYVGLGDRHGENILLDEFTSEATHDDFNCFDGLTFEKEPKVPPFRLLTRAMDAM 2278
Mei41  AVPLHESIERRKMFPTQLVLAHSPVQELRQRPATPHSHTERRNYRIRVA...SMVGYITGLGDRHGENILLACNDDAVHDDFNCFNGETFEVPEVPPFRLLTRAMVGM 2248
Mec1  W...QHTAVDGRCEFFYNEQ...VDKFPPELLYQPLENPFEPINWPNERNYVARSVAWAMVGHITGLGDRHGENILLDIQTSKVLHDDFCFEKGRLLVPEVPPFRLLTRNLLDL 2272
AtAtm  ...SSAKDKRRKAFVD...VCNFRPVMHYFFLEKFLPADWFKRLAYTRSWAASSVGYIVGLGDRHGENILLIDQATAEVVHIDLGVAFEQGMLRTPERVPPFRLLTRDIDGM 3729
X-ATM  KEVGRGPEERRYOMPLN...VCNFRPVMHYFFLEKFLPADWFKRLAYTRSWAASSVGYIVGLGDRHGENILLIDQATAEVVHIDLGVAFEQGMLRTPERVPPFRLLTRDIDGM 1445
Atm  KEVGRGPEERRYVDFND...VCNFRPVMHYFFLEKFLPADWFKRLAYTRSWAASSVGYITGLGDRHGENILLIDQATAEVVHIDLGVAFEQGMLRTPERVPPFRLLTRDIDGM 2918
Tel1  KAVGTRSNZERRKAYLK...ITNEIKPOLNFFPDSFFPLDWFKPKYKQVAASSVGYITGLGDRHGENILLDCSTGEPHIDLCIAPDQCKLLRTPERVPPFRLLTRDIDGM 2660

Atr  GILGEGFRRCCEBVTLAEMRNEVALNVEITLMD...KPVKQHSAPLNEGGEVNEKAKTHVLEDEQRLOGVI.....KTRNRVTCLEPESIEG 2618
Rad3  GITGVEGVFRRCCEBVTLAEMRNEVALNVEITLMD...RKKKSSVYVNNANEVLE.....IRKKFCGFM.....PGET.....LPEISIEG 2360
Mei41  GELGVEGFRRCCEBVTLAEMRNEVALNVEITLMD...RGAATA...ITKDWQRADRLQGHV.....K...EQQANSIPEISIEG 2328
Mec1  GILGEGFRRCCEBVTLAEMRNEVALNVEITLMD...RNDHSHIQAKVLRNKIRGI.....DPDQGLAVTSIAG 2342
AtAtm  GITGVEGVFRRCCEBVTLSVMRINREALLTIVEVFEHDPLYKALSPALKALQREDEVDGM...NILEGLQBEFENKNDATRALMRVKQLDGVCEGEMHSIIG 3830
X-ATM  GITGVEGVFRRCCEBVTLSVMRINREALLTIVEVFEHDPLYKALSPALKALQREDEVDGM...FLGGDPEE...NRNSCDSQSVNKVAERVLRLQPKLGVCEGEMHSIIG 1553
Atm  GITGVEGVFRRCCEBVTLSVMRINREALLTIVEVFEHDPLYKALSPALKALQREDETELHPILNADDQECKRNISDIDQSD...KVAERVLMRLQPKLGVCEGEMHSIIG 3030
Tel1  GITGVEGVFRRCCEBVTLSVMRINREALLTIVEVFEHDPLYKALSPALKALQREDETELHPILNADDQECKRNISDIDQSD...HMITFNFAVSKFISNNRNE...NQESYRALKGVCEKLMG...NG...LSVES 2761

Atr  HHHYLIOQADENLLQMLGWTMYM 2644
Rad3  QIQELIKSAVNEKNLVEMRIGWAAMP 2386
Mei41  QTNFLINEAKVNDLASMIGWGAFL 2354
Mec1  QTETLIOQADSEDLSPMIGWLEW 2368
AtAtm  QAQQLIQADIDDLSPMFGWAGMM 3856
X-ATM  QTNHLLIOQAMDENLLSRIPFGWKAIV 1579
Atm  QTNHLLIOQADIDDLSPMFGWKAIV 3056
Tel1  SQDILLIOQADDSLSLVIIMGWSRY 2787
    
```

**b)**



**c)**

	PI3-K	1	2	3	4	5	6
Atm	67/58	45/35	42/32	43/34	43/30	48/35	37/19
Atr	46/37	27/16	37/24	37/25	35/22	40/34	
Mei41	45/37	34/22	26/15	35/28	32/24		
Rad3	49/37	33/24	38/24	43/28			
Tel1	53/41	31/18	37/26				
Mec1	48/37	35/23					

**d)**

```

AtAtm  EFLVGNLVVMTRKYKRWEGEV
Dnmt3b  EFGILGLVWGLKGFSPWPAW
Msh6    DFGEGLVWVWKEGKPPWPCLV
MMSET   KYNVGLVWVSVSYPPWPCLV
CeSir2  NFOEGGLLVWVWKEGKPPWPAW
HDGF    EYKCGSLVPLKDKGPPWPERI
cons.   e f x x G d L v w x k x g x p w P x c x
    
```

Also, the steady state level of the transcript does not vary over 6 h after treatment of the cells with 100 Gy of  $\gamma$  rays, nor 1 h after irradiation with doses ranging from 0 to 200 Gy.

Expression levels of *AtATM* in different tissues was determined by semi-quantitative RT-PCR (Fig. 3). It is expressed at low levels in all tissues examined with slightly higher levels in


flower buds. This is similar to the situation in mammals, where *ATM* is expressed ubiquitously at low levels (9).

## DISCUSSION

We have identified an *Arabidopsis* homologue of *ATM* via sequence homology. The *AtATM* gene is situated on chromosome 3 between markers m409 and I18, respectively at 64.02 and 64.99 cM on the RI map.

From the genomic sequence we were able to determine by RT-PCR the complete structure of the *AtATM* mRNA. The transcript is 11.8 kb long and composed of 79 exons. To our knowledge, this is the longest *Arabidopsis* coding sequence to date. Out of the 79 exons, nine were not predicted by the MIPS annotation, two of which (numbers 59 and 74) have non-canonical splice sites, and eight have different boundaries than predicted by MIPS. This piece of data may be useful to improve current programs used to predict gene structure. The first exon is non-coding and may be involved in the stability of the transcript and/or regulation of transcription. This has been observed for other plant genes, such as *AtDMC1* (48). Alternative splicing in the 5'UTR and multiple polyadenylation sites have been described for the human *ATM* gene although the significance of these observations is currently unknown (49). Except for a putative alternative transcription initiation site, we did not detect any alternative splicing over the whole length of the gene. We cannot exclude the possibility that there is alternative splicing, however, because the RNA used for the RT-PCR analysis came from a single source, namely a cell suspension culture, and alternative splicing is known to reflect tissue specific expression (50–53). RT-PCR analysis on different tissues will have to be performed to determine if this the case for *AtATM*.

The predicted protein encoded by *AtATM* is 3856 amino acids long for a total molecular weight of 440 kDa. *AtATM* shows very strong homology to *Atm* and other related members of the family in the C-terminal region corresponding to the pi3K-I domain. This suggests that *AtATM* is a true member of this family and, like *Mec1*, *Tel1*, *mei-41*, *DNA-PK*, *Atr* and *Atm*, plays an important role in the cellular response to DNA damage. In addition, over the loosely defined upstream domain, *AtATM* is more closely related to human *Atm* than to the other members of the family, mouse *Atm* excluded. Although this may be taken as additional evidence that *AtATM* is an orthologue of human *Atm*, we cannot further predict the precise role of *AtATM*. For example, the yeast *TEL1* gene is



**Figure 3.** Expression of *AtATM* in response to IR and in different tissues. (a) Time course analysis by northern hybridisation of *AtATM* (top panel) and *ACT8* (bottom panel) transcript levels in cell suspensions after 100 Gy of  $\gamma$  irradiation. The *AtATM* and *ACT8* transcripts migrate at 12 and 1.6 kb respectively. (b) Dot blot hybridisation analysis of *AtATM* and *ACT8* transcript levels 1 h after different doses of irradiation. The following amounts of poly(A)<sup>+</sup> mRNA were deposited on the membrane: d<sub>0</sub>, 150 pg; d<sub>2</sub>, 75 pg; d<sub>4</sub>, 37.5 pg; and d<sub>8</sub>, 18.6 pg. (c) RT-PCR analysis of *AtATM* and *ACT8* transcript levels in major plant organs. 1, flowers; 2, flower buds; 3, leaves; 4, roots; 5, stems; 6, siliques. Total RNA (1 mg) was reverse transcribed and amplified for 30 and 25 cycles for *AtATM* and *ACT8* respectively. The RT-PCR products were separated on agarose gels and transferred to Nylon membranes which were then hybridised to gene-specific probes.

more closely related to *ATM* than *Mec1*, but the cellular phenotype of *AT* cells resembles that of *mec1* mutants (14,15). The phenotype of *mec1 tel1* double mutants, however, suggest they have partially overlapping roles (14,27,29). Thus, it is difficult to assign a particular role based simply on sequence homology. Nonetheless, Keegan *et al.* suggest that *rad3*, *Mec1*, *mei-41* and *Atr* on one hand and *Tel1* and *Atm* on the other

**Figure 2.** (Opposite) (a) Alignment of the C-terminal region spanning the Pi3 kinase-like domain of *AtATM* with six closely related members of the *Atm* family. The numbers on the right indicate the position of the residues for each protein. Amino acids identical to *AtATM* are boxed in black. Pale and dark grey boxes highlight amino acid identities between two and three or more proteins respectively, *AtATM* excluded. The alignment was performed with the PILEUP program (Genetics Computer Group, v.9.1). Vertical arrows indicate the three conserved residues of the kinase catalytic site, namely Asp 3681, Asn3686 and Asp3700 for *AtATM*. (b) Schematic drawing for the alignment of the *AtATM* translation product to related protein in mammals (*Atm*, *Atr*), *Drosophila melanogaster* (*Mei41*) and yeast (*Rad3*, *Tel1* and *Mec1*). Sequences were drawn to scale. Black boxes cover the Pi3-kinase-like region of strong homology, which is shared by all family members; boxes 1–5, the different homology domains between each protein and *AtATM*; box 6, the region of similarity shared by *AtATM* and *Atm* only. Thin lines for each sequence indicate region with no similarity (<20% identity). Alignments were performed against the *AtATM* sequence with each of the family members using the GAP program (Genetics Computer Group, v.9.1). (c) Percentages of amino acid similarity and identity for the domains defined in (b) between the different *Atm*-related proteins. In each box, the first number represents the similarity and the second number the identity. (d) Alignment of the PWWP domain of the following proteins: *AtATM*, *Dnmt3b* (accession number AAF04015), *hMsh6* (accession number AAB39212), *MMSET* type I (accession number AAF23369), *Caenorhabditis elegans* similar to *Sir2* (accession number U97193), and *HDGF* (accession number P51858). The alignment was generated as in (a).

hand constitute two distinctive subgroups of the family, based not only on structural but also functional similarities (54).

As in other members of the Atm family, the Pi3k-I domain of AtAtm is preceded by a very long N-terminal fragment. Sequence comparisons over this region again show that AtAtm is more closely related to Atm than to the other members and further underlines its status as a true Atm homologue. In Atm, a putative leucine zipper domain was identified and a fragment comprising this motif overexpressed in human cells has a dominant negative effect (43). AtAtm does not contain a putative leucine zipper. However a coiled-coil domain between residues 3249 and 3288 was predicted by two different programs. Since coiled-coil domains are involved in protein-protein interactions and particularly multimerisation, it is possible that AtAtm interacts with itself or other proteins via this domain.

Of particular interest, we noted the presence of a PWWP domain near the N-terminus of AtAtm. The existence of this conserved domain of approximately 25 amino acids was first described in the HDGF and two related proteins (46). It is present in a number of proteins including a mammalian *MutS* homologue (hMsh6 or G/T binding protein) (55,56), the mammalian DNA cytosine-5 methyl transferase 3B (Dnmt3b) (57), the multiple myeloma SET domain protein (58), a candidate gene for the Wolf-Hirschhorn syndrome WHSC1 (47), and an adenovirus E1A-associated protein (BS69) (59). These proteins play a role in various aspects of DNA metabolism including DNA repair, regulation of transcription and the cell cycle. Recently, it was found that the gene mutated in the human chromosome instability and immunodeficiency syndrome (ICF) is the *DNMT3B* gene (60,61). This disorder is due to the absence of methylation in heterochromatic regions, thus it is possible that the role of the PWWP domain is to direct the Dnmt3b proteins to certain chromosomal regions either by binding to other proteins or directly to DNA. The presence of other chromatin-associated domains such as the SET or bromo domains amongst the proteins with a PWWP domain further supports this assumption. Thus the PWWP domain of AtAtm may be of particular interest in a search for interacting partners or to test binding to DNA.

We were able to detect a 12 kb transcript hybridising to a specific *AtATM* probe in cell suspensions. The steady state levels of this transcript are fairly low and do not rise upon treatment with  $\gamma$  radiation over a 6 h period. In human cells, *ATM* expression is not induced by IR. Thus, like its human counterpart, AtAtm is likely to play a role very early in the response to genotoxic stress, via activation of its kinase activity upon binding to DNA breaks as was recently shown for human Atm (62).

Based on RT-PCR analysis of the expression in various tissues, it appears that *AtATM* is transcribed at low levels in all tissues, including tissues where few cell divisions occur like mature leaves. This is similar to the situation in mammals and raises the question of the role of these proteins in non-dividing cells.

In conclusion, we have characterised a plant homologue of *ATM*. The high degree of sequence conservation, and the fact that all members of this family of proteins from eukaryotic organisms as varied as yeast, *Drosophila* and mammals, play a critical role in DNA damage cell cycle checkpoints, suggest that *AtATM* does also play a similar role in *Arabidopsis*. We

plan to confirm this hypothesis by studying insertion mutants of *AtATM* obtained by a reverse genetics strategy.

## ACKNOWLEDGEMENTS

We thank Marie-Hélène Montané for critical reading of the manuscript and for supplying mRNAs, and Olivier Pierrugues for supplying plant tissues and total RNA. V.G. is funded by a predoctoral fellowship 'Contrat Formation Recherche' from the Commissariat à l'Énergie Atomique.

## REFERENCES

- Wang, J.Y. (1998) *Curr. Opin. Cell Biol.*, **10**, 240–247.
- Taylor, A., Harnden, D., Arlett, C., Harcourt, S., Lehmann, A., Stevens, S. and Bridges, B. (1975) *Nature*, **258**, 427–429.
- Shiloh, Y. (1997) *Annu. Rev. Genet.*, **31**, 635–662.
- Beamish, H., Williams, R., Chen, P. and Lavin, M.F. (1996) *J. Biol. Chem.*, **271**, 20486–20493.
- Houldsworth, J. and Lavin, M.F. (1980) *Nucleic Acids Res.*, **8**, 3709–3720.
- Foray, N., Priestley, A., Alsbeih, G., Badie, C., Capulas, E.P., Arlett, C.F. and Malaise, E.P. (1997) *Int. J. Radiat. Biol.*, **72**, 271–283.
- Dar, M.E., Winters, T.A. and Jorgensen, T.J. (1997) *Mutat. Res.*, **384**, 169–179.
- Savitsky, K., Sfez, S., Tagle, D.A., Ziv, Y., Sartiel, A., Collins, F.S., Shiloh, Y. and Rotman, G. (1995) *Hum. Mol. Genet.*, **4**, 2025–2032.
- Savitsky, K., Bar-Shira, A., Gilad, S., Rotman, G., Ziv, Y., Vanagaite, L., Tagle, D.A., Smith, S., Uziel, T., Sfez, S., Ashkenazi, M., Pecker, I., Frydman, M., Harnik, R., Patanjali, S.R., Simmons, A., Clines, G.A., Sartiel, A., Gatti, R.A., Chessa, L., Sanal, O., Lavin, M.F., Jaspers, N.G.J., Taylor, A.M.R., Arlett, C.F., Miki, T., Weissman, S.M., Lovett, M., Collins, F.S. and Shiloh, Y. (1995) *Science*, **268**, 1749–1753.
- Helliwell, S.B., Wagner, P., Kunz, J., Deuter-Reinhard, M., Henriquez, R. and Hall, M.N. (1994) *Mol. Biol. Cell*, **5**, 105–118.
- Kunz, J., Henriquez, R., Schneider, U., Deuter-Reinhard, M., Movva, N.R. and Hall, M.N. (1993) *Cell*, **73**, 585–596.
- Brown, E.J., Albers, M.W., Shin, T.B., Ichikawa, K., Keith, C.T., Lane, W.S. and Schreiber, S.L. (1994) *Nature*, **369**, 756–758.
- Sabatini, D.M., Erdjument-Bromage, H., Lui, M., Tempst, P. and Snyder, S.H. (1994) *Cell*, **78**, 35–43.
- Morrow, D.M., Tagle, D.A., Shiloh, Y., Collins, F.S. and Hieter, P. (1995) *Cell*, **82**, 831–840.
- Paulovitch, A.G. and Hartwell, L.H. (1995) *Cell*, **82**, 841–847.
- Bentley, N.J., Holtzman, D.A., Flaggs, G., Keegan, K.S., DeMaggio, A., Ford, J.C., Hoekstra, M. and Carr, A.M. (1996) *EMBO J.*, **15**, 6641–6651.
- Hari, K.L., Santerre, A., Sekelsky, J.J., McKim, K.S., Boyd, J.B. and Hawley, S.R. (1995) *Cell*, **82**, 815–821.
- Hartley, K.O., Gell, D., Smith, G.C., Zhang, H., Divecha, N., Connelly, M.A., Admon, A., Lees-Miller, S.P., Anderson, C.W. and Jackson, S.P. (1995) *Cell*, **82**, 849–856.
- Cliby, W.A., Roberts, C.J., Cimprich, K.A., Stringer, C.M., Lamb, J.R., Schreiber, S.L. and Friend, S.H. (1998) *EMBO J.*, **17**, 159–169.
- Canman, C.E., Lim, D.S., Cimprich, K.A., Taya, Y., Tamai, K., Sakaguchi, K., Appella, E., Kastan, M.B. and Siliciano, J.D. (1998) *Science*, **281**, 1677–1679.
- Banin, S., Moyal, L., Shieh, S., Taya, Y., Anderson, C.W., Chessa, L., Smorodinsky, N.I., Prives, C., Reiss, Y., Shiloh, Y. and Ziv, Y. (1998) *Science*, **281**, 1674–1677.
- Kastan, M.B., Zhan, Q., el-Deiry, W.S., Carrier, F., Jacks, T., Walsh, W.V., Plunkett, B.S., Vogelstein, B. and Fornace, A.J., Jr (1992) *Cell*, **71**, 587–597.
- Gately, D.P., Hittle, J.C., Chan, G.K. and Yen, T.J. (1998) *Mol. Biol. Cell*, **9**, 2361–2374.
- Shafman, T., Khanna, K.K., Kedar, P., Spring, K., Kozlov, S., Yen, T., Hobson, K., Gatei, M., Zhang, N., Watters, D., Egerton, M., Shiloh, Y., Kharbanda, S., Kufe, D. and Lavin, M.F. (1997) *Nature*, **387**, 520–523.
- Baskaran, R., Wood, L.D., Whitaker, L.L., Canman, C.E., Morgan, S.E., Xu, Y., Barlow, C., Baltimore, D., Wynshaw-Boris, A., Kastan, M.B. and Wang, J.Y. (1997) *Nature*, **387**, 516–519.
- Sun, Z., Fay, D.S., Marini, F., Foiani, M. and Stern, D.F. (1996) *Genes Dev.*, **10**, 395–406.

27. Sanchez, Y., Desany, B.A., Jones, W.J., Liu, Q., Wang, B. and Elledge, S.J. (1996) *Science*, **271**, 357–360.
28. Brush, G.S., Morrow, D.M., Hieter, P. and Kelly, T.J. (1996) *Proc. Natl Acad. Sci. USA*, **93**, 15075–15080.
29. Vialard, J.E., Gilbert, C.S., Green, C.M. and Lowndes, N.F. (1998) *EMBO J.*, **17**, 5679–5688.
30. Martinho, R.G., Lindsay, H.D., Flaggs, G., DeMaggio, A.J., Hoekstra, M.F., Carr, A.M. and Bentley, N.J. (1998) *EMBO J.*, **17**, 7239–7249.
31. Sanchez, Y., Wong, C., Thoma, R.S., Richman, R., Wu, Z., Piwnica-Worms, H. and Elledge, S.J. (1997) *Science*, **277**, 1497–1501.
32. Brown, A.L., Lee, C.H., Schwarz, J.K., Mitiku, N., Piwnica-Worms, H. and Chung, J.H. (1999) *Proc. Natl Acad. Sci. USA*, **96**, 3745–3750.
33. Axelos, M., Curie, C., Mazzolini, L., Bardet, C. and Lescure, B. (1992) *Plant Physiol. Biochem.*, **30**, 123–128.
34. Chandler, M.T., Tandeau de Marsac, N. and de Kouchkovsky, Y. (1972) *Can. J. Bot.*, **50**, 2265–2270.
35. Kloppstech, K., Otto, B. and Sierralta, W. (1991) *Mol. Gen. Genet.*, **225**, 468–473.
36. Montané, M.H., Dreyer, S., Triantaphylides, C. and Kloppstech, K. (1997) *Planta*, **202**, 293–302.
37. Sambrook, J., Fritsch, E.F. and Maniatis, T. (1989) *Molecular Cloning: A Laboratory Manual*, 2nd Edn. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
38. Altschul, S.F., Madden, T.L., Schaffer, A.A., Zhang, J., Zhang, Z., Miller, W. and Lipman, D.J. (1997) *Nucleic Acids Res.*, **25**, 3389–3402.
39. Minet, M., Dufour, M.E. and Lacroute, F. (1992) *Plant J.*, **2**, 417–422.
40. Choi, S.D., Creelman, R., Mullet, J. and Wing, R.A. (1995) *Weeds World*, **2**, 17–20.
41. Burge, C. and Karlin, S. (1997) *J. Mol. Biol.*, **268**, 78–94.
42. Keith, C.T. and Schreiber, S.L. (1995) *Science*, **270**, 50–51.
43. Morgan, S.E., Lovly, C., Pandita, T.K., Shiloh, Y. and Kastan, M.B. (1997) *Mol. Cell. Biol.*, **17**, 2020–2029.
44. Lim, D.S., Kirsch, D.G., Canman, C.E., Ahn, J.H., Ziv, Y., Newman, L.S., Darnell, R.B., Shiloh, Y. and Kastan, M.B. (1998) *Proc. Natl Acad. Sci. USA*, **95**, 10146–10151.
45. Khanna, K.K., Keating, K.E., Kozlov, S., Scott, S., Gatei, M., Hobson, K., Taya, Y., Gabrielli, B., Chan, D., Lees-Miller, S.P. and Lavin, M.F. (1998) *Nature Genet.*, **20**, 398–400.
46. Izumoto, Y., Kuroda, T., Harada, H., Kishimoto, T. and Nakamura, H. (1997) *Biochem. Biophys. Res. Commun.*, **238**, 26–32.
47. Stec, I., Wright, T.J., van Ommen, G.J., de Boer, P.A., van Haeringen, A., Moorman, A.F., Altherr, M.R. and den Dunnen, J.T. (1998) *Hum. Mol. Genet.*, **7**, 1071–1082.
48. Klimyuk, V.I. and Jones, J.D. (1997) *Plant J.*, **11**, 1–14.
49. Savitsky, K., Platzer, M., Uziel, T., Gilad, S., Sartiel, A., Rosenthal, A., Elroy-Stein, O., Shiloh, Y. and Rotman, G. (1997) *Nucleic Acids Res.*, **25**, 1678–1684.
50. Valcarcel, J. and Gebauer, F. (1997) *Curr. Biol.*, **7**, R705–R708.
51. Lou, H. and Gagel, R.F. (1998) *J. Endocrinol.*, **156**, 401–405.
52. Edwalds-Gilbert, G., Veraldi, K.L. and Milcarek, C. (1997) *Nucleic Acids Res.*, **25**, 2547–2561.
53. Chabot, B. (1996) *Trends Genet.*, **12**, 472–478.
54. Keegan, K.S., Holtzman, D.A., Plug, A.W., Christenson, E.R., Brainerd, E.E., Flaggs, G., Bentley, N.J., Taylor, E.M., Meyn, M.S., Moss, S.B., Carr, A.M., Ashley, T. and Hoekstra, M.F. (1996) *Genes Dev.*, **10**, 2423–2437.
55. Edelmann, W., Yang, K., Umar, A., Heyer, J., Lau, K., Fan, K., Liedtke, W., Cohen, P.E., Kane, M.F., Lipford, J.R., Yu, N., Crouse, G.F., Pollard, J.W., Kunkel, T., Lipkin, M., Kolodner, R. and Kucherlapati, R. (1997) *Cell*, **91**, 467–477.
56. Miyaki, M., Konishi, M., Tanaka, K., Kikuchi-Yanoshita, R., Muraoka, M., Yasuno, M., Igari, T., Koike, M., Chiba, M. and Mori, T. (1997) *Nature Genet.*, **17**, 271–272.
57. Okano, M., Xie, S. and Li, E. (1998) *Nature Genet.*, **19**, 219–220.
58. Chesi, M., Nardini, E., Lim, R.S., Smith, K.D., Kuehl, W.M. and Bergsagel, P.L. (1998) *Blood*, **92**, 3025–3034.
59. Hateboer, G., Gennissen, A., Ramos, Y.F., Kerkhoven, R.M., Sonntag-Buck, V., Stunnenberg, H.G. and Bernards, R. (1995) *EMBO J.*, **14**, 3159–3169.
60. Hansen, R.S., Wijmenga, C., Luo, P., Stanek, A.M., Canfield, T.K., Weemaes, C.M. and Gartler, S.M. (1999) *Proc. Natl Acad. Sci. USA*, **96**, 14412–14417.
61. Xu, G.-L., Bestor, T.H., Bourc'his, D., Hsieh, C.-L., Tommerup, N., Bugge, M., Hulten, M., Qu, X., Russo, J.J. and Viegas-Péquignot, E. (1999) *Nature*, **402**, 187–191.
62. Smith, G.C., Cary, R.B., Lakin, N.D., Hann, B.C., Teo, S.H., Chen, D.J. and Jackson, S.P. (1999) *Proc. Natl Acad. Sci. USA*, **96**, 11134–11139.